These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 33558360)

  • 21. A protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE Study).
    Jorsal A; Wiggers H; Holmager P; Nilsson B; Nielsen R; Boesgaard TW; Kumme A; Møller JE; Videbæk L; Kistorp C; Gustafsson I; Tarnow L; Flyvbjerg A
    BMJ Open; 2014 May; 4(5):e004885. PubMed ID: 24844271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
    Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Colesevelam: in pediatric patients with heterozygous familial hypercholesterolemia.
    Perry CM
    Paediatr Drugs; 2010 Apr; 12(2):133-40. PubMed ID: 20218749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Different Effects of Once-weekly and Once-daily Administered GLP-1RA Semaglutide and Liraglutide on Bile Acid Diarrhea.
    Kårhus ML; Knudsen E; Knop FK
    JCEM Case Rep; 2023 Jan; 1(1):luac004. PubMed ID: 37908253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The analysis of gut microbiota in patients with bile acid diarrhoea treated with colesevelam.
    Kumar A; Quraishi MN; Al-Hassi HO; El-Asrag ME; Segal JP; Jain M; Steed H; Butterworth J; Farmer A; Mclaughlin J; Beggs A; Brookes MJ
    Front Microbiol; 2023; 14():1134105. PubMed ID: 37007510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial.
    Kuiper EM; van Erpecum KJ; Beuers U; Hansen BE; Thio HB; de Man RA; Janssen HL; van Buuren HR
    Hepatology; 2010 Oct; 52(4):1334-40. PubMed ID: 20683930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Epidemiology of Bile Acid Diarrhea in Denmark.
    Kårhus ML; Ellegaard AM; Winther-Jensen M; Hansen S; Knop FK; Kårhus LL
    Clin Epidemiol; 2023; 15():1173-1181. PubMed ID: 38089008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial.
    Armstrong MJ; Barton D; Gaunt P; Hull D; Guo K; Stocken D; Gough SC; Tomlinson JW; Brown RM; Hübscher SG; Newsome PN;
    BMJ Open; 2013 Nov; 3(11):e003995. PubMed ID: 24189085
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Study protocol of the randomised placebo-controlled GLOBE trial:
    Hulst AH; Visscher MJ; Godfried MB; Thiel B; Gerritse BM; Scohy TV; Bouwman RA; Willemsen MGA; Hollmann MW; DeVries JH; Preckel B; Hermanides J
    BMJ Open; 2018 Jun; 8(6):e022189. PubMed ID: 29866735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects.
    Davidson MH; Dillon MA; Gordon B; Jones P; Samuels J; Weiss S; Isaacsohn J; Toth P; Burke SK
    Arch Intern Med; 1999 Sep; 159(16):1893-900. PubMed ID: 10493319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of a glucagon-like peptide-1 agonist and restrictive versus liberal oxygen supply in patients undergoing coronary artery bypass grafting or aortic valve replacement: study protocol for a 2-by-2 factorial designed, randomised clinical trial.
    Wiberg S; Kjaergaard J; Møgelvang R; Møller CH; Kandler K; Ravn H; Hassager C; Køber L; Nilsson JC
    BMJ Open; 2021 Nov; 11(11):e052340. PubMed ID: 34740932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation.
    Bizino MB; Jazet IM; de Heer P; van Eyk HJ; Dekkers IA; Rensen PCN; Paiman EHM; Lamb HJ; Smit JW
    Diabetologia; 2020 Jan; 63(1):65-74. PubMed ID: 31690988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Not Available].
    Kårhus ML; Ellegaard AM; Rix I; Knop FK
    Ugeskr Laeger; 2023 May; 185(20):. PubMed ID: 37264870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
    le Roux CW; Astrup A; Fujioka K; Greenway F; Lau DCW; Van Gaal L; Ortiz RV; Wilding JPH; Skjøth TV; Manning LS; Pi-Sunyer X;
    Lancet; 2017 Apr; 389(10077):1399-1409. PubMed ID: 28237263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.
    Farr OM; Sofopoulos M; Tsoukas MA; Dincer F; Thakkar B; Sahin-Efe A; Filippaios A; Bowers J; Srnka A; Gavrieli A; Ko BJ; Liakou C; Kanyuch N; Tseleni-Balafouta S; Mantzoros CS
    Diabetologia; 2016 May; 59(5):954-65. PubMed ID: 26831302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia.
    McKenney J; Jones M; Abby S
    Curr Med Res Opin; 2005 Sep; 21(9):1403-12. PubMed ID: 16197659
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial.
    Halawi H; Khemani D; Eckert D; O'Neill J; Kadouh H; Grothe K; Clark MM; Burton DD; Vella A; Acosta A; Zinsmeister AR; Camilleri M
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):890-899. PubMed ID: 28958851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnea-hypnoea index (AHI).
    Sprung VS; Kemp GJ; Wilding JP; Adams V; Murphy K; Burgess M; Emegbo S; Thomas M; Needham AJ; Weimken A; Schwab RJ; Manuel A; Craig SE; Cuthbertson DJ
    BMJ Open; 2020 Jul; 10(7):e038856. PubMed ID: 32699168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Remission of Bile Acid Malabsorption Symptoms Following Treatment With the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide.
    Kårhus ML; Brønden A; Røder ME; Leotta S; Sonne DP; Knop FK
    Gastroenterology; 2019 Aug; 157(2):569-571. PubMed ID: 30965026
    [No Abstract]   [Full Text] [Related]  

  • 40. Are bile acid malabsorption and bile acid diarrhoea important causes of loose stool complicating cancer therapy?
    Phillips F; Muls AC; Lalji A; Andreyev HJ
    Colorectal Dis; 2015 Aug; 17(8):730-4. PubMed ID: 25728737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.